转移性结直肠癌全身治疗现状与新兴概念
综述总结近二十年来转移性结直肠癌全身治疗的主要进展,指出尽管化疗和靶向治疗不断发展,患者5年生存率仍约10-25%。错配修复缺陷或微卫星不稳定肿瘤对免疫检查点抑制剂反应极好,而多数CRC对免疫治疗无应答,肿瘤基质介导的免疫抑制机制是重要原因,调控肿瘤细胞和基质以使微卫星稳定肿瘤对免疫治疗敏感是新兴方向。
要点
- 转移性CRC患者5年生存率约10-25%,多数患者最终进展。
- 错配修复缺陷或微卫星不稳定CRC对免疫检查点抑制剂反应极好。
- 肿瘤基质介导免疫抑制是多数CRC对免疫治疗无应答的重要机制。
核心结论
- 转移性CRC全身治疗持续发展但多数患者仍进展,仅错配修复缺陷或微卫星不稳定肿瘤对免疫检查点抑制剂反应极好。
- 肿瘤基质介导的免疫抑制机制是多数CRC对免疫治疗无应答的重要原因,调控肿瘤细胞和基质使微卫星稳定肿瘤对免疫治疗敏感是新兴方向。
研究设计与样本
- 综述,总结近几十年来CRC全身治疗的主要进展,并概述新兴和即将实施的治疗策略及临床和临床前研究概念。
主要发现
- 转移性CRC患者5年生存率约10-25%。
- 小部分错配修复缺陷或微卫星不稳定CRC患者对免疫检查点抑制剂反应极好,证明CRC原则上可对免疫治疗敏感,即使转移阶段也可实现长期疾病稳定。
- 多数CRC对免疫治疗无应答的原因尚待阐明,近期证据提示肿瘤基质(包括结直肠肿瘤微环境中的非免疫细胞)介导免疫抑制机制。
临床怎么用
- 转移性CRC全身治疗包括细胞毒性化疗和靶向治疗,多数患者最终进展。
- 错配修复缺陷或微卫星不稳定CRC可考虑免疫检查点抑制剂治疗,部分患者可实现长期疾病稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer (CRC) is one of the most common malignant cancers and its incidence is steadily rising particularly in young patients. While screening measures and the widespread availability of surgical treatment have led to an impressive improvement of prognosis within the overall CRC population, patients with metastatic CRC still face 5-year survival rates of around 10-25%. Despite continuous development of new systemic treatment strategies that include cytotoxic chemotherapy and targeted therapy, most patients with metastatic CRC eventually progress. However, a small proportion of patients with mismatch repair-deficient or microsatellite unstable CRC responds exceptionally well to treatment with immune checkpoint inhibitors, thereby proving that CRC is in principle amenable to immunotherapy and showing that long-term disease stabilisation can be achieved even in metastasised stages. However, the reasons for the lack of response to immunotherapy in the vast majority of CRC cases remain to be elucidated. Yet, recent evidence suggests that the tumour stroma, which includes non-immune cells in the colorectal tumour microenvironment, mediates immunosuppressive mechanisms that prevent effective immunotherapy. These findings open new avenues for the development of advanced immunotherapies for CRC. In this review, we summarise major developments in the systemic therapy of CRC within the last couple of decades, provide an overview of emerging and soon-to-be implemented therapeutic strategies and present concepts from clinical and preclinical research to manipulate tumour cells and the tumour stroma to sensitise microsatellite stable colorectal tumours to immunotherapy.
引用
- Steup C, Kennel KB, Neurath MF, et al. Current and emerging concepts for systemic treatment of metastatic colorectal cancer. Gut. 2025. PMID: 41047178. doi:10.1136/gutjnl-2025-335412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。